Lilly shares trade down after fourth-quarter profits falls

Back to TopCommentsE-mailPrintBookmark and Share

Shares of Eli Lilly and Co. dipped in morning trading after the drugmaker reported a dip in fourth-quarter earnings and a steep dive in sales of its newest drug, Effient.

Indianapolis-based Lilly’s stock price fell as much as 3 percent at one point this morning to $35.27.

Profit dropped 10 percent to $999 million in the quarter ended Dec. 31, down from $1.12 billion in the same period a year earlier. Those totals exclude the impact of Lilly’s agreement to sell its Lafayette manufacturing plant in October 2009 and its purchase of ImClone Systems in November 2008.

On the same basis, Lilly’s fourth-quarter profit per share was 91 cents, down from $1.02 a year ago.

Wall Street analysts expected a profit of 92 cents per share, excluding the extraordinary items, according to a survey by Thomson Financial network.

Lilly’s stock price has been depressed for more than a year as investors and analysts have taken a show-me attitude about Lilly’s pipeline of experimental drugs, which the company is counting on to replace five blockbuster drugs that will lose sales to cheaper generics starting this year and running to 2014.

Effient, a blood thinner Lilly launched in late summer, was supposed to fill a large chunk of the multibillion-dollar gap those drugs will leave. But in the fourth quarter, the drug’s worldwide sales went from bad to worse.

Lilly and its partner, Japan-based Daichii Sankyo Co. Ltd., sold just $3.8 million of Effient in the fourth quarter, down from $22.6 million in the third quarter.

"For all the attention this product has received over the past few years, the first six months of sales are very underwhelming," Bernstein analyst Dr. Tim Anderson said in a Thursday morning research note, according to the Associated Press.

Lilly officials have pleaded for patience for Effient, saying the first step has been to get Effient on the approved formularies of U.S. health insurers and European national health programs.

“Even considering all of that, I would think you would be disappointed to the early results of the product,” Catherine Arnold, a Credit Suisse analyst, said during a conference call with Lilly executives this morning.

Goldman Sachs analyst Jami Rubin asked Lilly CEO John Lechleiter when Lilly would “reset expectations” for Effient.

But Lechleiter said Lilly remains confident the drug will turn out to be a success.

“We feel just as good about Effient today as we did when we launched the product,” Lechleiter responded. He added, “I’m very reluctant to say after six months we can say this or we can say that. We’re going to stay with it.”

In prepared remarks, Lechleiter highlighted Lilly’s performance for all of 2009, during which Lilly’s profits rose 16 percent to $4.85 billion, or $4.42 per share.

For 2010, Lilly reaffirmed its profit forecast of $4.65 to $4.85 per share.

In the fourth quarter, Lilly’s sales rose by 14 percent to $5.9 billion. The growth was driven mainly by higher prices in the United States and by higher volume in the rest of the world.

Its cancer drug Alimta continued to be the fastest-growing product, with fourth-quarter sales rising 64 percent to $523.6 million.

Excluding the impact of Lilly’s extraordinary events, the company would have earned a profit of $915.4 million, or 83 cents per share. In the fourth quarter a year ago, Lilly recorded a loss of $3.6 billion, or $3.31 per share.


Post a comment to this story

We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
You are legally responsible for what you post and your anonymity is not guaranteed.
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
Subscribe to IBJ
  1. The Walgreens did not get a lot of traffic. It was not located on the corner of the intersection, and not really visible from Emerson. Meanwhile the CVS there is huge and right on the corner. I am guessing a lot of people drove by a million times and never knew the Walgreens was there. Although, with the new Walmart market going in, that area could really see a lot of increase in traffic soon.

  2. You folks don't have a clue. There is a legal way to enter this country and to get aid. This left unchecked could run us to ruin quickly. I also heard that 'supporters' were getting major $$ to take them in? Who's monitoring this and guess who pays the bill? I support charitable organizations... but this is NOT the way to do it!

  3. Apparently at some time before alcohol has been served at the fair. The problem is that beer or wine used to be a common drink for people before soft drinks and was not thought to be that unusual. Since many folks now only drink to see how much they can drink or what kind of condition they can end up in it becomes more problematic. Go to Europe and its no big deal just as if you had sodas of milk to drink everyday. Its using common sense that is lacking now days.

  4. To address the epic failure of attracting race fans to both the Indy 500 and Brickyard 400 would take too much of my time to write. Bottom line Boles is clueless and obviously totally out of touch with the real paying fan base. I see nothing but death spin coming for the Brickyard, just like Indy. Get somebody in a place of power that understands what race fans want.

  5. I am a race fan through & through. It doesn't matter if it's Indy cars or Nascar. I love a great race. I go to several other tracks each year and you can see the entire track. I know Indy has tradition, but fans want to see the entire race. I sit in the Penthouse, am almost 60 years old, and would like to see a better TV screen in turn 1 so you can see the entire race. Then I think Indy needs to install an escalator so us old folks can make it up to the Penthouse and down again if we want more options to purchase food and drinks. Just a race fans opinion. Lights won't make the race any better, but you might be able to see the TV better at night. Turn 1's screen needs replaced with a better and bigger screen.